CL2023001361A1 - Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas - Google Patents
Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetasInfo
- Publication number
- CL2023001361A1 CL2023001361A1 CL2023001361A CL2023001361A CL2023001361A1 CL 2023001361 A1 CL2023001361 A1 CL 2023001361A1 CL 2023001361 A CL2023001361 A CL 2023001361A CL 2023001361 A CL2023001361 A CL 2023001361A CL 2023001361 A1 CL2023001361 A1 CL 2023001361A1
- Authority
- CL
- Chile
- Prior art keywords
- cyclopentathiophen
- activating factor
- platelet activating
- receptor antagonists
- factor receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20207719 | 2020-11-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023001361A1 true CL2023001361A1 (es) | 2023-11-03 |
Family
ID=73543025
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023001361A CL2023001361A1 (es) | 2020-11-16 | 2023-05-11 | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas |
| CL2024000317A CL2024000317A1 (es) | 2020-11-16 | 2024-02-01 | Derivados de ciclopentatiofencarboxamida como antagonistas del receptor del factor de activación de plaquetas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024000317A CL2024000317A1 (es) | 2020-11-16 | 2024-02-01 | Derivados de ciclopentatiofencarboxamida como antagonistas del receptor del factor de activación de plaquetas |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11766443B2 (enExample) |
| EP (1) | EP4244229A1 (enExample) |
| JP (3) | JP7465368B2 (enExample) |
| KR (1) | KR20230109692A (enExample) |
| CN (2) | CN116745300A (enExample) |
| AR (1) | AR124070A1 (enExample) |
| AU (1) | AU2021379248A1 (enExample) |
| CA (1) | CA3200710A1 (enExample) |
| CL (2) | CL2023001361A1 (enExample) |
| CO (1) | CO2023005894A2 (enExample) |
| CR (2) | CR20230211A (enExample) |
| DO (1) | DOP2023000090A (enExample) |
| EC (1) | ECSP23036210A (enExample) |
| IL (1) | IL302769A (enExample) |
| JO (1) | JOP20230107A1 (enExample) |
| MX (1) | MX2023005678A (enExample) |
| PE (1) | PE20231855A1 (enExample) |
| SA (1) | SA523440809B1 (enExample) |
| TW (1) | TWI913356B (enExample) |
| WO (1) | WO2022101377A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN119842821A (zh) * | 2025-01-06 | 2025-04-18 | 华中科技大学 | 稳定表达血小板活化因子受体的细胞株、构建方法及应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3502392A1 (de) | 1985-01-25 | 1986-07-31 | Boehringer Ingelheim KG, 6507 Ingelheim | Neue thieno-triazolo-1,4-diazepino-2- carbonsaeureamide, verfahren zu ihrer herstellung und pharmazeutische zusammensetzungen |
| DD265405A5 (de) * | 1986-01-21 | 1989-03-01 | Boehringer Ingelheim Kg,De | Neue thieno-1,4-diazepine |
| PH30676A (en) | 1986-07-22 | 1997-09-16 | Boehringer Ingelhein Kg | Hetrazepine compounds which have useful pharmaceutical utility |
| MC1999A1 (fr) * | 1987-12-18 | 1990-01-26 | Hoffmann La Roche | Composes tricycliques |
| US4959361A (en) * | 1987-12-18 | 1990-09-25 | Hoffmann-La Roche Inc. | Triazolo(4,3-A)(1,4)benzodiazepines and thieno (3,2-F)(1,2,4)triazolo(4,3-A)(1,4)diazepine compounds which have useful activity as platelet activating factor (PAF) antagonists |
| EP0368175A1 (de) | 1988-11-06 | 1990-05-16 | Boehringer Ingelheim Kg | 3S,7S-3-(Morpholinocarbonyl)-5-(2-chlorphenyl)-7,10-dimethyl-3,4-dihydro-2H,7H-cyclopenta[4,5]thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin. |
| DE3909012A1 (de) | 1989-03-18 | 1990-09-20 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen hetrazepinen |
| DE4010528A1 (de) | 1990-04-02 | 1991-10-17 | Boehringer Ingelheim Kg | Praeparativ chromatographisches trennverfahren zur herstellung enantiomerenreiner hetrazepine |
| JP2959598B2 (ja) | 1990-10-12 | 1999-10-06 | 吉富製薬株式会社 | 光学活性なチエノトリアゾロジアゼピン化合物 |
| CN1033327C (zh) | 1991-04-23 | 1996-11-20 | 东丽株式会社 | 三环三唑并衍生物的制造方法 |
| DE4132763A1 (de) | 1991-10-02 | 1993-04-08 | Boehringer Ingelheim Kg | Verbessertes verfahren zur herstellung von enantiomerenreinen saeureamiden hetrazepinoider struktur |
| FR2779652B1 (fr) | 1998-06-15 | 2001-06-08 | Sod Conseils Rech Applic | Utilisation de diazepines pour la preparation de medicaments destines a traiter les etats pathologiques ou les maladies dans lesquels un des recepteurs de la somatostatine est implique |
| US20050032713A1 (en) * | 2002-03-27 | 2005-02-10 | Wurtman Richard J. | Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents |
| US7749996B2 (en) | 2006-11-20 | 2010-07-06 | Alantos Pharmaceutical Holdings, Inc. | Heterotricyclic metalloprotease inhibitors |
-
2021
- 2021-11-12 CR CR20230211A patent/CR20230211A/es unknown
- 2021-11-12 JP JP2022562298A patent/JP7465368B2/ja active Active
- 2021-11-12 KR KR1020237020295A patent/KR20230109692A/ko active Pending
- 2021-11-12 CN CN202180076849.5A patent/CN116745300A/zh active Pending
- 2021-11-12 US US17/524,759 patent/US11766443B2/en active Active
- 2021-11-12 WO PCT/EP2021/081459 patent/WO2022101377A1/en not_active Ceased
- 2021-11-12 CA CA3200710A patent/CA3200710A1/en active Pending
- 2021-11-12 PE PE2023001605A patent/PE20231855A1/es unknown
- 2021-11-12 MX MX2023005678A patent/MX2023005678A/es unknown
- 2021-11-12 IL IL302769A patent/IL302769A/en unknown
- 2021-11-12 CN CN202311341729.0A patent/CN117624188B/zh active Active
- 2021-11-12 CR CR20260053A patent/CR20260053A/es unknown
- 2021-11-12 AU AU2021379248A patent/AU2021379248A1/en active Pending
- 2021-11-12 EP EP21806745.2A patent/EP4244229A1/en active Pending
- 2021-11-15 AR ARP210103159A patent/AR124070A1/es unknown
- 2021-11-15 TW TW110142333A patent/TWI913356B/zh active
-
2023
- 2023-05-08 CO CONC2023/0005894A patent/CO2023005894A2/es unknown
- 2023-05-11 CL CL2023001361A patent/CL2023001361A1/es unknown
- 2023-05-11 DO DO2023000090A patent/DOP2023000090A/es unknown
- 2023-05-16 JO JOJO/P/2023/0107A patent/JOP20230107A1/ar unknown
- 2023-05-16 SA SA523440809A patent/SA523440809B1/ar unknown
- 2023-05-17 EC ECSENADI202336210A patent/ECSP23036210A/es unknown
- 2023-07-14 US US18/221,936 patent/US20230355638A1/en active Pending
-
2024
- 2024-02-01 CL CL2024000317A patent/CL2024000317A1/es unknown
- 2024-03-29 JP JP2024055696A patent/JP7810743B2/ja active Active
-
2026
- 2026-01-22 JP JP2026008915A patent/JP2026090284A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20220160725A1 (en) | 2022-05-26 |
| CL2024000317A1 (es) | 2024-07-12 |
| AU2021379248A1 (en) | 2023-06-22 |
| TW202237620A (zh) | 2022-10-01 |
| CN117624188B (zh) | 2026-08-07 |
| JP7465368B2 (ja) | 2024-04-10 |
| CN117624188A (zh) | 2024-03-01 |
| PE20231855A1 (es) | 2023-11-21 |
| DOP2023000090A (es) | 2023-06-15 |
| JP7810743B2 (ja) | 2026-02-03 |
| CA3200710A1 (en) | 2022-05-19 |
| CO2023005894A2 (es) | 2023-05-29 |
| EP4244229A1 (en) | 2023-09-20 |
| CN116745300A (zh) | 2023-09-12 |
| JP2026090284A (ja) | 2026-06-02 |
| AU2021379248A9 (en) | 2024-10-10 |
| US11766443B2 (en) | 2023-09-26 |
| JP2023521200A (ja) | 2023-05-23 |
| ECSP23036210A (es) | 2023-06-30 |
| IL302769A (en) | 2023-07-01 |
| CR20230211A (es) | 2023-07-13 |
| SA523440809B1 (ar) | 2024-10-08 |
| WO2022101377A1 (en) | 2022-05-19 |
| US20230355638A1 (en) | 2023-11-09 |
| JOP20230107A1 (ar) | 2023-05-16 |
| KR20230109692A (ko) | 2023-07-20 |
| TWI913356B (zh) | 2026-02-01 |
| MX2023005678A (es) | 2023-05-26 |
| CR20260053A (es) | 2026-03-24 |
| JP2024099528A (ja) | 2024-07-25 |
| AR124070A1 (es) | 2023-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2021000038A (es) | COMPUESTOS DE PIRAZOLO[3,4-b]PIRIDINA COMO INHIBIDORES DE CINASAS TAM Y MET | |
| ECSP21080966A (es) | Derivados de 1,1-dióxido de 3-amino-4h-benzo[e][1,2,4] tiadiazina como inhibidores de mrgx2 | |
| UY38553A (es) | Inhibidores de cdk2 | |
| UY28059A1 (es) | Nuevos derivados de dihidropirimido (4,5-d) pirimidona sustituida por amino. fabricacion y uso de los mismos como agentes farmaceuticos. | |
| JOP20210116A1 (ar) | مشتقات أمينو ترايازولو كوينازولين بها استبدال في الموضع-9 كمضادات مستقبل أدينوزين، تركيبات صيدلانية واستخدامها | |
| CO2021006114A2 (es) | Derivados de 2,3-dihidro-1h-pirrolo[3,4-c]piridin-1-ona como inhibidores de hpk1 para el tratamiento del cáncer | |
| AR029215A1 (es) | Derivados de benzazol y tautomeros de los mismos utiles en el tratamiento de desordenes en los sistemas de autoinmunidad y neuronales, uso de dichos derivados en la preparacion de composiciones farmaceuticas aplicables en el tratamiento de dichos desordenes, metodo prar inhibir la expresion y/o acti | |
| CO5560573A2 (es) | Derivados activos de amino-ftalazinona como inhibidores de quinasa, proceso para su preparacion y composiciones farmaceuticas que los contienen | |
| ECSP045367A (es) | "derivados de bencimidazol utiles como antagonistas de histamina h3" | |
| CL2019002601A1 (es) | Derivados pirazol[1,5-a]pirimidina sustituidos con alicíclicos farmacológicamente activos. | |
| AR085219A1 (es) | 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc | |
| CL2025001220A1 (es) | Análogos, sales, composiciones y métodos de uso de la psilocibina | |
| CL2022002101A1 (es) | Derivados de carboxamida heteroaromática como inhibidores de la calicreína plasmática | |
| CO2023005894A2 (es) | Derivados de ciclopentatiofen carboxamida como antagonistas del receptor del factor de activación de plaquetas | |
| AR038483A1 (es) | Derivados de quinazolinona, un proceso para su produccion, composiciones farmaceuticas y el uso de los mismos para la fabricacion de un medicamento como agonistas canabinoides | |
| CO6361995A2 (es) | Derivados de isoquinolinona como antagonistas de nk3 | |
| ECSP22080683A (es) | 3-fenoxiazetidin-1-YL-pirazinas sustituidas que tienen Actividad agonista de GPR52 | |
| UY28357A1 (es) | Derivados de benzimidazol, composiciones que los contienen, preparación de los mismos y sus usos | |
| MX2021016068A (es) | Derivados de isoquinolinona como inhibidores de la proteina quinasa rock y usos del mismo. | |
| CO2025010725A2 (es) | Compuestos moduladores de receptores de dopamina d3/d2 | |
| CO2021000782A2 (es) | Agentes inhibidores de ask1 | |
| PE20191549A1 (es) | Derivados sustituidos de 6-(1h-pirazol-1-il)pirimidin-4-amina y usos de los mismos | |
| CO2024015547A2 (es) | Antagonistas de at2r y usos de estos | |
| CL2023003117A1 (es) | Compuestos agonistas de gpr35 | |
| AR131509A1 (es) | Inhibidores del inflamasoma nlrp3 |